Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 298

Sort by

Sort Order Select

Journal Articles

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood (2021) 137 (23): 3212–3217.

https://doi.org/10.1182/blood.2021010867

Published: 2021

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Simon Heidegger, MD, Alexander Wintges, Florian Stritzke, Katja Steiger, Paul-Albert Koenig, Thomas Engleitner, Julius Clemens Fischer, Vladimir Makarov, Christof Winter, Roland Rad, Marcel R.M. van den Brink, MD PhD, Jürgen Ruland, Florian Bassermann, MD PhD, Timothy Chan, Tobias Haas, MD, Hendrik Poeck, MD

Blood (2019) 134 (Supplement_1): 624.

https://doi.org/10.1182/blood-2019-128724

Published: 2019

Journal Articles

Identification of an Immune Risk Score to Predict the Prognosis of Acute Myeloid Leukemia

Yang Liang, PhD, Yun Wang, Yan-Yu Cai, Siliang Chen, Run-Cong Nie, Zhe-Yuan Qin, PhD, Fang Hu, Weida Wang, MD, Yu-Jun Dai, PhD

Blood (2019) 134 (Supplement_1): 708.

https://doi.org/10.1182/blood-2019-126733

Published: 2019

Journal Articles

Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells

Alicia Vaca, PhD, Mariela Sivina, Karen Clise-Dwyer, PhD, Ekaterina Kim, MS, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Dan Li, PhD, Qing Ma, PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 1746.

https://doi.org/10.1182/blood-2019-125827

Published: 2019

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders

Yuchi Honaker, PhD, Karen Sommer, PhD, Noelle Dahl, Yufei Xiang, MD, PhD, Christina Lopez, PhD, Samuel Scharffenberger, Michelle Christian, Troy R. Torgerson, MD PhD, Andrew M. Scharenberg, MD, David J. Rawlings, MD

Blood (2019) 134 (Supplement_1): 2071.

https://doi.org/10.1182/blood-2019-131946

Published: 2019

Journal Articles

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

Alison Tarke, Valentina Ferrari, BA, Hannah Fields, Luca Ferrari, Franco Ferrari, PhD, Tiffany N Tanaka, MD, Rafael Bejar, MD PhD, Antonella Vitiello, Dr. Pharm., Thomas A Lane, MD

Blood (2019) 134 (Supplement_1): 4870.

https://doi.org/10.1182/blood-2019-131474

Published: 2019

Journal Articles

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Karthik Gnanapandithan, MD MS, Prakash Kharel, MD, Alyssa Grimshaw, MSLIS, Smith Giri, MBBS

Blood (2019) 134 (Supplement_1): 3606.

https://doi.org/10.1182/blood-2019-132203

Published: 2019

Journal Articles

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

Sean I. Tracy, MD PhD, Can Hekim, MSc,PhD, Michael Farrar, PhD

Blood (2019) 134 (Supplement_1): 1345.

https://doi.org/10.1182/blood-2019-124205

Published: 2019

Journal Articles

CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to Checkpoint Therapy

Sary El Daker, PhD, Qi Gao, MLS, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 1513.

https://doi.org/10.1182/blood-2019-130346

Published: 2019

Journal Articles

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Joshua C Pritchett, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Jose C Villasboas, MD, Andrew L. Feldman, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 1517.

https://doi.org/10.1182/blood-2019-131145

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Adam Greenbaum, MD PhD, Ajay K. Gopal, MD, Jonathan R. Fromm, MD PhD, A McGarry Houghton, MD

Blood (2019) 134 (Supplement_1): 1518.

https://doi.org/10.1182/blood-2019-126217

Published: 2019

Journal Articles

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Takahiro Kobayashi, MD PhD, Yuki Fujioka, MD PhD, Sho Ikeda, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 1792.

https://doi.org/10.1182/blood-2019-125649

Published: 2019

Journal Articles

Novel Simultaneous Single Cell mRNA and Protein Expression Profiling Identifies Distinct Treg and T Effector Signatures in the Bone Marrow of MDS Patients

Jessica Ann Timms, Susann Winter, Steven Hargreaves, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Uwe Platzbecker, MD, Shahram Kordasti, MD PhD

Blood (2019) 134 (Supplement_1): 2980.

https://doi.org/10.1182/blood-2019-130355

Published: 2019

Journal Articles

Identifying Primary Immune Deficiencies in Patients with Autoimmune Cytopenias

Emma Westermann-Clark, MD, Krisztian Csomos, PhD, Rachel Cruz Nieves, Other, Cristina Meehan, BS, Boglarka Ujhazi, BS, Maryssa Ellison, Jennifer Lynne Root Mayer, MD, Jonathan Metts, MD, Marisol Betensky, MDMPH, Panida Sriaroon, MD, Irmel Ayala, MD, Jolan Walter, MD PhD

Blood (2019) 134 (Supplement_1): 2328.

https://doi.org/10.1182/blood-2019-130289

Published: 2019

Journal Articles

Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)

Michelle J. Cox, Fabrice Lucien-Matteoni, PhD, Reona Sakemura, MD PhD, Justin C. Boysen, Yohan Kim, MS, Michael J. Hansen, Claudia Manriquez Roman, Erin E. Tapper, Sydney B. Crotts, Kendall J. Schick, Mehrdad Hefazi, MD, Paulina Roman Moreno, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 679.

https://doi.org/10.1182/blood-2019-125272

Published: 2019

Journal Articles

Polymorphisms in Inflammatory Genes Modulate the Occurrence of Clinical Complications in Patients with Sickle Cell Disease

Blood (2019) 134 (Supplement_1): 4825.

https://doi.org/10.1182/blood-2019-124218

Published: 2019

Journal Articles

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Nicole Sunseri, MD PhD, Xiufen Chen, PhD, Noemie Wald, PhD, Julie Preillon, PhD, Sonali M. Smith, MD, Gregory Driessens, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 391.

https://doi.org/10.1182/blood-2019-131493

Published: 2019

Journal Articles

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

Alexander I. Ngwube, MD, Niketa C. Shah, MD, David Jacobsohn, MD, Edward Dela Ziga, MD, Shalini Shenoy, MD

Blood (2019) 134 (Supplement_1): 370.

https://doi.org/10.1182/blood-2019-126405

Published: 2019

NARROW

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Identification of an Immune Risk Score to Predict the Prognosis of Acute Myeloid Leukemia

Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to Checkpoint Therapy

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Novel Simultaneous Single Cell mRNA and Protein Expression Profiling Identifies Distinct Treg and T Effector Signatures in the Bone Marrow of MDS Patients

Identifying Primary Immune Deficiencies in Patients with Autoimmune Cytopenias

Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)

Polymorphisms in Inflammatory Genes Modulate the Occurrence of Clinical Complications in Patients with Sickle Cell Disease

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only